BMS’ schizophrenia treatment reduces symptoms in Phase III trial

“KarXT had a favourable impact on weight and metabolic parameters in the trial.”

8 Likes

Wooohoooo 15 character

1 Like

I’m pretty happy with Vraylar, but this sounds good too.

2 Likes

We should know FDA decision and pricing if approved in 5 months or less.By the way, BMS spent so much obtaining this drug, their profits were temporarily down.

4 Likes

I can’t imagine the price for them to ship this to Singapore… Hope it’s 1300 usd or less

1 Like

That is an indication that the drug will be expensive.

2 Likes

I hope so 151515

With huge acquisition cost and novel mechanism, I expect it to be more than $1600, maybe much more.

3 Likes